All In Biotech

Drug Trial Radar · NCT01096849

A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)

A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis

Last checked: Nov 20, 2026Latest source record: Aug 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Jul 13, 2010

Primary completion

Apr 3, 2012

Study completion Apr 3, 2012

Sponsor

Lead sponsor
Achaogen, Inc.Industry
Sponsor type
Industry
First posted
Mar 31, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).

Conditions

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis

Interventions

  • levofloxacinDrug

  • plazomicinDrug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) PopulationTime frame: Day 1 to TOC (Day 12)
  2. Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) PopulationTime frame: Day 1 to TOC (Day 12)
  3. Percentage of Patients With Treatment-Emergent Adverse Events (TEAE)Time frame: Day 1 to the end of study (Day 40)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.